News
Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback